Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mengzhen Lai

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Medicinal Chemistry|July 13, 2019
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR<sup>L858R/T790M/C797S</sup>)Jiayi Shen, Tao Zhang, Su-Jie Zhu, et al.
Frontiers in Pharmacology|January 2, 2023
ASK120067 potently suppresses B-cell or T-cell malignancies <i>in vitro</i> and <i>in vivo</i> by inhibiting BTK and ITKPeiran Song, Gang Bai, Shingpan Chan, et al.
Journal of Cancer|January 6, 2023
Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation <i>in vitro</i> and <i>in vivo</i>Mengzhen Lai, Tao Zhang, Hao Chen, et al.
Molecular Cancer|August 19, 2023
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistanceTao Zhang, Rong Qu, Shingpan Chan, et al.
Molecular Cancer|August 18, 2021
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistanceTao Zhang, Rong Qu, Shingpan Chan, et al.
Molecular Cancer|May 15, 2020
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistanceTao Zhang, Rong Qu, Shingpan Chan, et al.
Medcomm|April 27, 2026
Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR InhibitorMengzhen Lai, Jiaying Chen, Ye Qin, et al.
Cancer Science|December 2, 2021
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivoYingqiang Liu, Mengzhen Lai, Shan Li, et al.
Signal Transduction and Targeted Therapy|August 14, 2024
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activationTao Zhang, Zilu Pan, Jing Gao, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Medicinal Chemistry|July 13, 2019
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR<sup>L858R/T790M/C797S</sup>)Jiayi Shen, Tao Zhang, Su-Jie Zhu, et al.
Frontiers in Pharmacology|January 2, 2023
ASK120067 potently suppresses B-cell or T-cell malignancies <i>in vitro</i> and <i>in vivo</i> by inhibiting BTK and ITKPeiran Song, Gang Bai, Shingpan Chan, et al.
Journal of Cancer|January 6, 2023
Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation <i>in vitro</i> and <i>in vivo</i>Mengzhen Lai, Tao Zhang, Hao Chen, et al.
Molecular Cancer|August 19, 2023
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistanceTao Zhang, Rong Qu, Shingpan Chan, et al.
Molecular Cancer|August 18, 2021
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistanceTao Zhang, Rong Qu, Shingpan Chan, et al.
Molecular Cancer|May 15, 2020
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistanceTao Zhang, Rong Qu, Shingpan Chan, et al.
Medcomm|April 27, 2026
Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR InhibitorMengzhen Lai, Jiaying Chen, Ye Qin, et al.
Cancer Science|December 2, 2021
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivoYingqiang Liu, Mengzhen Lai, Shan Li, et al.
Signal Transduction and Targeted Therapy|August 14, 2024
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activationTao Zhang, Zilu Pan, Jing Gao, et al.
Pageof 2